Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
AssigneeCelgene Corporation
InventorJerome B. Zeldis
Life of this patent
Estimating the term…
Abstract
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Claims17
A method of treating mantle cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.
A method of treating mantle cell lymphoma, which comprises administering to a patient having mantle cell lymphoma from about 5 mg to about 50 mg of 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a therapeutically effective amount of a second active agent selected from a hematopoietic growth factor, a cytokine, an anti-cancer agent, an antibiotic, a cox-2 inhibitor, a corticosteroid, rituximab, or a combination thereof.
Dependencies are inferred from the claim text.